Company: SXTPW
Filing Date: 2025-08-27
Form Type: DEF 14A
Source: 0001213900-25-080878
Chunk: 20

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-27
Form: DEF 14A
Chunk 20
---
 investment promotion agency, where he facilitated foreign direct investment into Australian research
in neglected tropical diseases, infectious diseases, autoimmune diseases, cancer and other therapeutic areas. Paul was the founder and
Executive Chairman of Bio-Link from 2005 to 2014, a privately owned biotechnology business development company. His work at Bio-Link involved
the commercialization of discovery, pre-clinical and early-stage clinical programs undertaken by Australian biotech companies and medical
research institutions. Paul has served on a number of Boards of Directors, and he is a Fellow of the Australian Institute of Company Directors.
The Board concluded that Mr. Field’s background and leadership experiences in the biotechnology industry qualify him to be a member
of the Board.

Family Relationships

There are no family relationships among any of
our executive officers or directors.

Legal Proceedings

To the best of our knowledge, none of our directors
or executive officers have, during the past ten years, been involved in any legal proceedings described in subparagraph (f) of Item 401
of Regulation S-K.

<div align='center'>10

CORPORATE GOVERNANCE</div>

The business and affairs of 60 Degrees Pharmaceuticals
are managed under the direction of the Board. The Board believes that good corporate governance is a critical factor in achieving business
success and in fulfilling the Board’s responsibilities to the Company’s stockholders. The Board believes that its practices
align management and stockholder interests.

The Governance section of the Company website
makes available the Company’s corporate governance materials, including the Certificate of Incorporation, as corrected, as of the
date of this Proxy Statement, and bylaws, the charters for each Board committee, the Company’s Code of Conduct and information about
how to report concerns about the Company. To access these documents on the Company’s website, please visit https://60degreespharma.com.

Board Composition/Election

Our Board presently consists of five (5) directors
whose terms expire at this Annual Meeting. Our directors are elected annually. All of the current directors have served on the Board since
the effective date of the Company’s registration statement for its initial public offering in July 2023.

The Board has fixed the number of directors at
five (5).

As discussed in more detail later in this section,
the Board has determined that three (3) of the five (5) individuals standing for election are independent under the rules of Nasdaq.

Board Meetings

The Board met a total of five times during fiscal
year 2024